Tags: obesity | drug

Eli Lilly Exec: More Out of Pocket Payments for Obesity Drug

Eli Lilly Exec: More Out of Pocket Payments for Obesity Drug

Monday, 10 June 2024 08:57 PM EDT

 A top Eli Lilly (LLY.N) executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.

Patrik Jonsson, president of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said a mid-single digit percentage of patients paid the full list price out of pocket for Zepbound in the first quarter of 2024 in the U.S., which compares to the low single digits for Mounjaro.

© 2025 Thomson/Reuters. All rights reserved.


US
A top Eli Lilly (LLY.N) executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.Patrik Jonsson, president of Lilly Diabetes and Obesity, speaking at a Goldman Sachs...
obesity, drug
82
2024-57-10
Monday, 10 June 2024 08:57 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved